Cassava Sciences Revenue 2011-2026 | SAVA

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Cassava Sciences

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-	-	-	-	-	-	-	41.1 M	10.9 M	11.5 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
41.1 M	10.9 M	21.2 M

Quarterly Revenue Cassava Sciences

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	35.2 M	1.96 M	1.96 M	1.96 M	2.47 M	2.72 M	2.72 M	2.97 M	2.75 M	2.75 M	2.75 M	3.24 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
35.2 M	1.96 M	5.29 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
BioNTech SE BNTX	482 M	$ 97.57	2.17 %	$ 27.2 B	Germany
Aligos Therapeutics ALGS	2.19 M	$ 8.49	6.25 %	$ 83.9 M	USA
Alterity Therapeutics Limited ATHE	109 K	$ 3.63	-2.42 %	$ 8.73 B	Australia
I-Mab IMAB	88 M	-	-	$ 866 M	China
AlloVir ALVR	165 K	-	4.14 %	$ 49.1 M	USA
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	70.9 M	-	2.54 %	$ 160 B	France
Applied Therapeutics APLT	9.99 M	-	-	$ 8.42 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
Esperion Therapeutics ESPR	403 M	$ 2.15	-0.69 %	$ 447 M	USA
Evogene Ltd. EVGN	3.85 M	$ 0.83	2.5 %	$ 27.9 M	Israel
Amphastar Pharmaceuticals AMPH	720 M	$ 20.87	2.45 %	$ 976 M	USA
Genmab A/S GMAB	10.1 B	$ 28.23	-0.07 %	$ 18 B	Danmark
Grifols, S.A. GRFS	7.21 B	$ 8.24	0.3 %	$ 6.83 B	Spain
GT Biopharma GTBP	27 K	$ 0.37	-0.92 %	$ 2.04 M	USA
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA
Halozyme Therapeutics HALO	1.4 B	$ 66.86	-1.42 %	$ 8.01 B	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Adverum Biotechnologies ADVM	1 M	-	-	$ 86.2 M	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	7.5 M	-	5.93 %	$ 314 M	Canada
Harmony Biosciences Holdings HRMY	868 M	$ 28.5	-1.35 %	$ 1.64 B	USA
AgeX Therapeutics AGE	130 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	236 M	$ 1.43	2.14 %	$ 368 M	USA
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
Can-Fite BioPharma Ltd. CANF	853 K	$ 2.91	-0.26 %	$ 4.79 M	Israel
Aptinyx APTX	1 M	-	-39.0 %	$ 4.57 M	USA
Aquestive Therapeutics AQST	44.5 M	$ 4.18	2.45 %	$ 447 M	USA
Aravive ARAV	9.14 M	-	-13.39 %	$ 1.45 M	USA
Arcutis Biotherapeutics ARQT	376 M	$ 23.96	-1.03 %	$ 3.05 B	USA
AIkido Pharma AIKI	123 M	-	1.93 %	$ 17.4 M	USA
Celldex Therapeutics CLDX	1.54 M	$ 32.21	-0.09 %	$ 2.14 B	USA
Autolus Therapeutics plc AUTL	75.4 M	$ 1.49	-0.34 %	$ 397 M	Britain
Incyte Corporation INCY	5.14 B	$ 94.65	-1.48 %	$ 18.5 B	USA
Cidara Therapeutics CDTX	1.28 M	-	-	$ 1.41 B	USA
Innate Pharma S.A. IPHA	9 M	$ 1.48	4.61 %	$ 235 M	France
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	66.4 M	$ 2.57	0.78 %	$ 16.1 M	USA
AstraZeneca PLC AZN	58.7 B	-	-	$ 96.9 B	Britain
Inventiva S.A. IVA	9.2 M	$ 5.15	-2.09 %	$ 138 M	France